Patents by Inventor Shui-on Leung

Shui-on Leung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10613099
    Abstract: The present invention describes the generation of an anti-idiotype single-chain Fv (scFv) antibody specific for the murine (RFB4), chimeric (SM03) and humanized (SM06) versions of an anti-CD22 antibody (“the anti-CD22 antibodies”). The present invention further describes the construction of a murine IgG2a/kappa immunoglobulin carrying the variable region sequences of the anti-idiotype scFv sequences. Additionally, the present invention provides a cell line capable of producing an anti-idiotype murine antibody specific for “the anti-CD22 antibodies.” The present invention is directed against a method for identifying and evaluating the activities and concentration of “the anti-CD22 antibodies.” Additionally, the present invention provides a method for evaluating serum concentration of “the anti-CD22 antibodies” that are being used clinically. The present invention is also directed against a method to detect HAMA, HACA and HAHA responses in patients treated with “the anti-CD22 antibodies.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: April 7, 2020
    Assignee: Sinomab Bioscience Limited
    Inventor: Shui-on Leung
  • Patent number: 10111542
    Abstract: The present invention relates to a simple holder which includes an elastic first sheet structure. The first sheet structure has a first side and a second side which are opposite to each other, a hole located between the first side and the second side, a first cutting slit formed by cutting from the edge of the first side inwards, and a second cutting slit formed by cutting from the edge of the second side inwards. The center of the hole is located between the first cutting slit and the second cutting slit. The first sheet structure can be bent to make the first cutting slit slotting into the second cutting slit for locking. The simple holder provided by the present invention is formed by sheets and is thus convenient to be manufactured, transported and stored.
    Type: Grant
    Filed: October 6, 2015
    Date of Patent: October 30, 2018
    Inventor: On Shui Leung
  • Publication number: 20170295971
    Abstract: The present invention relates to a simple holder which includes an elastic first sheet structure. The first sheet structure has a first side and a second side which are opposite to each other, a hole located between the first side and the second side, a first cutting slit formed by cutting from the edge of the first side inwards, and a second cutting slit formed by cutting from the edge of the second side inwards. The center of the hole is located between the first cutting slit and the second cutting slit. The first sheet structure can be bent to make the first cutting slit slotting into the second cutting slit for locking. The simple holder provided by the present invention is formed by sheets and is thus convenient to be manufactured, transported and stored.
    Type: Application
    Filed: October 6, 2015
    Publication date: October 19, 2017
    Inventor: On Shui Leung
  • Publication number: 20160363597
    Abstract: The present invention describes the generation of an anti-idiotype single-chain Fv (scFv) antibody specific for the murine (RFB4), chimeric (SM03) and humanized (SM06) versions of an anti-CD22 antibody (“the anti-CD22 antibodies”). The present invention further describes the construction of a murine IgG2a/kappa immunoglobulin carrying the variable region sequences of the anti-idiotype scFv sequences. Additionally, the present invention provides a cell line capable of producing an anti-idiotype murine antibody specific for “the anti-CD22 antibodies.” The present invention is directed against a method for identifying and evaluating the activities and concentration of “the anti-CD22 antibodies.” Additionally, the present invention provides a method for evaluating serum concentration of “the anti-CD22 antibodies” that are being used clinically. The present invention is also directed against a method to detect HAMA, HACA and HAHA responses in patients treated with “the anti-CD22 antibodies.
    Type: Application
    Filed: June 20, 2016
    Publication date: December 15, 2016
    Applicant: SINOMAB BIOSCIENCE LIMITED
    Inventor: Shui-on LEUNG
  • Patent number: 9371396
    Abstract: The present invention describes the generation of an anti-idiotype single-chain Fv (scFv) antibody specific for the murine (RFB4), chimeric (SM03) and humanized (SM06) versions of an anti-CD22 antibody (the anti-CD22 antibodies). The present invention further describes the construction of a murine IgG2a/kappa immunoglobulin carrying the variable region sequences of the anti-idiotype scFv sequences. Additionally, the present invention provides a cell line capable of producing an anti-idiotype murine antibody specific for the anti-CD22 antibodies. The present invention is directed against a method for identifying and evaluating the activities and concentration of the anti-CD22 antibodies. Additionally, the present invention provides a method for evaluating serum concentration of the anti-CD22 antibodies that are being used clinically. The present invention is also directed against a method to detect HAMA, HACA and HAHA responses in patients treated with the anti-CD22 antibodies.
    Type: Grant
    Filed: June 16, 2013
    Date of Patent: June 21, 2016
    Assignee: Sinomab Bioscience Limited
    Inventor: Shui-on Leung
  • Publication number: 20150175711
    Abstract: The present invention describes the generation of an anti-idiotype single-chain Fv (scFv) antibody specific for the murine (RFB4), chimeric (SM03) and humanized (SM06) versions of an anti-CD22 antibody (the anti-CD22 antibodies). The present invention further describes the construction of a murine IgG2a/kappa immunoglobulin carrying the variable region sequences of the anti-idiotype scFv sequences. Additionally, the present invention provides a cell line capable of producing an anti-idiotype murine antibody specific for the anti-CD22 antibodies. The present invention is directed against a method for identifying and evaluating the activities and concentration of the anti-CD22 antibodies. Additionally, the present invention provides a method for evaluating serum concentration of the anti-CD22 antibodies that are being used clinically. The present invention is also directed against a method to detect HAMA, HACA and HAHA responses in patients treated with the anti-CD22 antibodies.
    Type: Application
    Filed: June 16, 2013
    Publication date: June 25, 2015
    Applicant: SINOMAB BIOSCIENCE LIMITED
    Inventor: Shui-on Leung
  • Patent number: 8771694
    Abstract: A chimeric LL2 monoclonal antibody (mAb) is described in which the variable regions of the murine LL2 mAb are recombinantly joined to the human constant region domains, which retains the immunospecificity and B-cell lymphoma and leukemia cell internalization capacity of the murine LL2 (mAB), and which exhibits reduced human anti-mouse antibody production activity (HAMA). A humanized LL2 mAb is described in which the CDRs are recombinantly joined to a framework sequence of human variable regions, and subsequently linked to human constant region domains, which retains the immunospecificity and B-lymphoma and leukemia cell internalization capacities of the murine and chimeric LL2 mABs, and has the potential for exhibiting reduced HAMA. Isolated DNAs encoding the LL2 variable and CDR framework regions are described. Conjugates of chimeric and humanized chimeric LL2 antibodies with cytotoxic agents or labels find use in therapy and diagnosis of B-cell lymphomas and leukemias.
    Type: Grant
    Filed: November 16, 2001
    Date of Patent: July 8, 2014
    Assignee: Immunomedics, Inc.
    Inventors: Shui-on Leung, Hans Hansen
  • Patent number: 7943343
    Abstract: The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a targetable conjugate. The targetable conjugate encompasses a hapten to which antibodies have been prepared. In preferred embodiments, the hapten is histamine-succinyl-glycine (HSG). In more preferred embodiments, the at least one arm comprises the CDR sequences of the HSG-binding 679 antibody. The targetable conjugate is attached to one or more therapeutic and/or diagnostic agents. The invention provides constructs and methods for producing the bispecific antibodies or antibody fragments, as well as methods for using them and kits comprising them.
    Type: Grant
    Filed: October 20, 2009
    Date of Patent: May 17, 2011
    Assignee: Immunomedics, Inc.
    Inventors: Hans J. Hansen, Gary L. Griffiths, Shui-on Leung, William J. McBride, Zhengxing Qu
  • Patent number: 7919087
    Abstract: The present invention provides humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific that bind to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies, other malignancies in which the cells are reactive with CD74, and autoimmune diseases, and methods of treatment and diagnosis.
    Type: Grant
    Filed: May 29, 2007
    Date of Patent: April 5, 2011
    Assignee: Immunomedics, Inc.
    Inventors: Hans J. Hansen, Shui-on Leung, Zhengxing Qu, David M. Goldenberg
  • Publication number: 20100284906
    Abstract: The present invention provides humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific that bind to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies, other malignancies in which the cells are reactive with CD74, and autoimmune diseases, and methods of treatment and diagnosis.
    Type: Application
    Filed: June 1, 2010
    Publication date: November 11, 2010
    Applicant: IMMUNOMEDICS, INC.
    Inventors: Hans J. Hansen, Shui-on Leung, Zhengxing Qu, David M. Goldenberg
  • Publication number: 20100266497
    Abstract: The present invention provides humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific that bind to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies, other malignancies in which the cells are reactive with CD74, and autoimmune diseases, and methods of treatment and diagnosis.
    Type: Application
    Filed: June 7, 2010
    Publication date: October 21, 2010
    Applicant: IMMUNOMEDICS, INC.
    Inventors: Hans J. Hansen, Shui-on Leung, Zhengxing Qu, David M. Goldenberg
  • Publication number: 20100197896
    Abstract: Current humanization approaches for immunoglobulins focus mostly on modifying the framework regions into human sequences. Herein is provided a method for humanizing antibody complementarity-determining regions (CDRs) through functional humanization to reduce the potential immunogenicity of non-human CDR-containing antibodies. CDRs with high sequence homology to the parent CDR are identified from a database of human CDR sequences. One or more human CDRs that are highly homologous to the parent CDR sequence can be used to replace the corresponding CDRs of murine immunoglobulins (or their humanized, or re-engineered versions). Human CDRs that improve or have minimal effects on the antigen binding affinity and specificity are adopted.
    Type: Application
    Filed: May 16, 2008
    Publication date: August 5, 2010
    Inventors: Shui-on Leung, Pui Fan Wong
  • Publication number: 20100158803
    Abstract: The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a targetable conjugate. The targetable conjugate encompasses a hapten to which antibodies have been prepared. In preferred embodiments, the hapten is histamine-succinyl-glycine (HSG). In more preferred embodiments, the at least one arm comprises the CDR sequences of the HSG-binding 679 antibody. The targetable conjugate is attached to one or more therapeutic and/or diagnostic agents. The invention provides constructs and methods for producing the bispecific antibodies or antibody fragments, as well as methods for using them and kits comprising them.
    Type: Application
    Filed: January 7, 2010
    Publication date: June 24, 2010
    Applicant: IMMUNOMEDICS, INC.
    Inventors: Hans J. Hansen, Gary L. Griffiths, Shui-on Leung, William J. McBride, Zhengxing Qu
  • Publication number: 20100136626
    Abstract: The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a targetable conjugate. The targetable conjugate encompasses a hapten to which antibodies have been prepared. In preferred embodiments, the hapten is histamine-succinyl-glycine (HSG). In more preferred embodiments, the at least one arm comprises the CDR sequences of the HSG-binding 679 antibody. The targetable conjugate is attached to one or more therapeutic and/or diagnostic agents. The invention provides constructs and methods for producing the bispecific antibodies or antibody fragments, as well as methods for using them and kits comprising them.
    Type: Application
    Filed: October 20, 2009
    Publication date: June 3, 2010
    Applicant: IMMUNOMEDICS, INC.
    Inventors: Hans J. Hansen, Gary L. Griffiths, Shui-on Leung, William J. McBride, Zhengxing Qu
  • Publication number: 20100137156
    Abstract: Immunoglobulin libraries are provided that contain randomly assembled FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4 sequences of heavy or light chain immunoglobulin variable regions. The libraries exhibit a degree of repertoire diversity not found in natural immune systems and can be used to express novel immunoglobulins. The libraries can be used for screening antibodies with the target specificity of interest. The resultant antibodies can be fully human and non-immunogenic.
    Type: Application
    Filed: March 10, 2008
    Publication date: June 3, 2010
    Inventors: Shui-on Leung, Pui Fan Wong, Chi Wai Kwong, Yip Sum Chan
  • Patent number: 7666415
    Abstract: The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a targetable conjugate. The targetable conjugate encompasses a hapten to which antibodies have been prepared. In preferred embodiments, the hapten is histamine-succinyl-glycine (HSG). In more preferred embodiments, the at least one arm comprises the CDR sequences of the HSG-binding 679 antibody. The targetable conjugate is attached to one or more therapeutic and/or diagnostic agents. The invention provides constructs and methods for producing the bispecific antibodies or antibody fragments, as well as methods for using them and kits comprising them.
    Type: Grant
    Filed: June 9, 2009
    Date of Patent: February 23, 2010
    Assignee: Immunomedics, Inc.
    Inventors: Hans J. Hansen, Gary L. Griffiths, Shui-on Leung, William J. McBride, Zhengxing Qu
  • Publication number: 20100015048
    Abstract: The present invention provides humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific that bind to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies, other malignancies in which the cells are reactive with CD74, and autoimmune diseases, and methods of treatment and diagnosis.
    Type: Application
    Filed: September 3, 2009
    Publication date: January 21, 2010
    Applicant: IMMUNOMEDICS, INC.
    Inventors: Hans J. Hansen, Shui-on Leung, Zhengxing Qu, David M. Goldenberg
  • Publication number: 20090246131
    Abstract: The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a targetable conjugate. The targetable conjugate encompasses a hapten to which antibodies have been prepared. In preferred embodiments, the hapten is histamine-succinyl-glycine (HSG). In more preferred embodiments, the at least one arm comprises the CDR sequences of the HSG-binding 679 antibody. The targetable conjugate is attached to one or more therapeutic and/or diagnostic agents. The invention provides constructs and methods for producing the bispecific antibodies or antibody fragments, as well as methods for using them and kits comprising them.
    Type: Application
    Filed: June 9, 2009
    Publication date: October 1, 2009
    Applicant: IMMUNOMEDICS, INC.
    Inventors: Hans J. Hansen, Gary L. Griffiths, Shui-on Leung, William J. McBride, Zhengxing Qu
  • Patent number: 7563439
    Abstract: The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a linker moiety. The linker moiety encompasses a hapten to which antibodies have been prepared. In preferred embodiments, the hapten is histamine-succinyl-glycine (HSG). In more preferred embodiments, the at least one arm comprises the CDR sequences of the HSG-binding 679 antibody. The antigenic linker is conjugated to one or more therapeutic or diagnostic agents or enzymes. In one embodiment, the invention provides constructs and methods for producing the bispecific antibodies or antibody fragments, as well as methods for using them.
    Type: Grant
    Filed: October 24, 2007
    Date of Patent: July 21, 2009
    Assignee: Immunomedics, Inc.
    Inventors: Hans J. Hansen, Gary L. Griffiths, Shui-on Leung, William J. McBride, Zhengxing Qu
  • Patent number: 7541440
    Abstract: The present invention provides humanized, chimeric and human MN3 antibodies, fusion proteins, and fragments thereof. The antibodies, fusion proteins, and fragments thereof, as well as combinations with other suitable antibodies, are useful for the treatment and diagnosis of granulocyte related disorders and diseases, such as leukemia.
    Type: Grant
    Filed: September 29, 2003
    Date of Patent: June 2, 2009
    Assignee: Immunomedics, Inc.
    Inventors: David M. Goldenberg, Hans J. Hansen, Shui-on Leung